Health
Investigational combo therapy shows promise in treating TP53 mutant MDS and AML patients – News-Medical.Net
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow.
Myelodysplastic Syndromes (MDS) and acute myeloid leukemia (AML) are rare hematologic malignancies of the bone marrow. They can occur spontaneously or secondary to treatment for other cancers, so called therapy related disease, which is frequently associated with a mutation of the tumor suppressor gene TP53. Standard treatment for these patients includes hypomethylating agents such as azacitidine or decitabine but unfortunately outcomes are very poor.
Patients with TP53-mutant disease, which is…
-
General15 hours agoMan dies in daylight shooting in Sydney’s north-west
-
Business18 hours agoOrd Minnett names 2 ASX 200 shares to buy
-
Noosa News19 hours agoResident rushed to hospital with multiple burns as house engulfed in flames in Woodridge
-
Noosa News17 hours agoWhy the Brisbane City Hall clock has fallen silent